Differences in reported outcomes in industry-funded vs nonfunded studies assessing thromboprophylaxis after total joint arthroplasty

dc.authorid0000-0003-0926-3029
dc.contributor.authorGroff, Hannah
dc.contributor.authorAzboy, İbrahim
dc.contributor.authorParvizi, Javad
dc.date.accessioned10.07.201910:49:13
dc.date.accessioned2019-07-10T19:50:04Z
dc.date.available10.07.201910:49:13
dc.date.available2019-07-10T19:50:04Z
dc.date.issued2018
dc.departmentİstanbul Medipol Üniversitesi, Tıp Fakültesi, Cerrahi Tıp Bilimleri Bölümü, Ortopedi ve Travmatoloji Ana Bilim Dalı
dc.descriptionWOS: 000446993500007
dc.descriptionPubMed ID: 30017220
dc.description.abstractBackground: There are numerous studies discussing thromboprophylaxis after total joint arthroplasty (TJA), with varying conclusions. Patient inclusion criteria may be different for each study, which may lead to selection bias and misrepresentation of data. This study aimed to investigate if industry funding impacted patient demographics and overall reported outcomes of studies analyzing venous thromboembolism (VTE) prevention after TJA. Methods: Electronic searches were completed using Ovid, PubMed, and Embase databases. Studies were included if (1) they are published in the English language between 2000 and 2016; (2) they included patients undergoing total hip arthroplasty (THA) or total knee arthroplasty (TKA); and (3) they evaluated prevention and control of postoperative VTE with at least one of the following thromboprophylactic agents: aspirin, enoxaparin, dalteparin, dabigatran, apixaban, rivaroxaban, dabigatran, ximelagatran, fondaparinux, or coumadin. Data were extracted and analyzed via mixed-effect logistic regression. Results: Fifty-seven studies were included; 29 were industry funded, and 28, nonfunded. There were no significant differences between patient's age, body mass index, or revision exclusions between funded and nonfunded studies. Funded studies reported less pulmonary embolisms, fewer events of major bleeding, and significantly less 90-day mortality compared with nonfunded studies. Conclusion: Industry-funded studies reported less pulmonary embolisms, major bleeding, and mortality compared with nonfunded studies. Detailed demographic data were missing from the literature, and we were unable to demonstrate the cause of different reported outcomes between industry-funded and nonfunded studies. Further investigations should be aimed toward understanding how funded studies report less adverse outcomes in analyzing VTE after TJA.
dc.identifier.citationGroff, H., Azboy, İ. ve Parvizi, J. (2018). Differences in reported outcomes in industry-funded vs nonfunded studies assessing thromboprophylaxis after total joint arthroplasty. Journal of Arthroplasty, 33(11), 3398-3401. https://dx.doi.org/10.1016/j.arth.2018.06.025
dc.identifier.doi10.1016/j.arth.2018.06.025
dc.identifier.endpage3401
dc.identifier.issn0883-5403
dc.identifier.issn1532-8406
dc.identifier.issue11
dc.identifier.scopusqualityQ1
dc.identifier.startpage3398
dc.identifier.urihttps://dx.doi.org/10.1016/j.arth.2018.06.025
dc.identifier.urihttps://hdl.handle.net/20.500.12511/1868
dc.identifier.volume33
dc.identifier.wosqualityQ1
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakScopus
dc.indekslendigikaynakPubMed
dc.language.isoen
dc.publisherChurchill Livingstone Inc Medical Publishers
dc.relation.ispartofJournal of Arthroplastyen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanı
dc.rightsinfo:eu-repo/semantics/embargoedAccess
dc.subjectTotal Joint Arthroplasty
dc.subjectHip
dc.subjectKnee
dc.subjectVenous Thromboembolism
dc.subjectIndustry Funding
dc.subjectOutcomes
dc.titleDifferences in reported outcomes in industry-funded vs nonfunded studies assessing thromboprophylaxis after total joint arthroplasty
dc.typeArticle

Dosyalar

Orijinal paket
Listeleniyor 1 - 1 / 1
Küçük Resim Yok
İsim:
Azboy, İ..pdf
Boyut:
376.5 KB
Biçim:
Adobe Portable Document Format
Açıklama:
Tam Metin / Full Text